Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy (RETILASE trial)

Recruiting

You are on the General Public view
  • Source

    -
    Public Title Efficacy and safety of retinal rejuvenation using Ellex 2RT laser in age-related maculopathy (RETILASE trial)
    Acronym RETILASE
    Source of Record URL http://isrctn.org/ISRCTN87850962
  • Trial

    -
    Health Condition(s) or Problem Topic: Eye; Subtopic: Eye (all Subtopics); Disease: Ophthalmology
    Lay Summary Not provided at time of registration (from ISRCTN)
    Who can enter the trial 1. Patients of either sex aged 55 years or over 2. Diagnosis of age related maculopathy that meet the criteria of large drusen (=125 µ) in at least 1 eye 3. Best corrected visual acuity in the study eye between 50 to 90 ETDRS letters at baseline visit 4. Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs 5. No previous macular laser therapy to study eye 6. Written informed consent and willingness and ability to be followed up for 24 months.; Target Gender: Male & Female; Upper Age Limit 90 years ; Lower Age Limit 55 years
    Who cannot enter the trial 1. Drusenoid PED, Choroidal neovascularisation and geographic atrophy in the study eye 2. Macular ischaemia (FAZ > 1000µm in diameter or moderate perifoveal capillary loss in fluorescein angiogram) or diabetic retinopathy 3. Macular oedema of any cause such as wet AMD, diabetic macular oedema, pseudophakic macular oedema or taut posterior hyaloid 4. Co-existent ocular disease that in the investigator?s discretion would lead to decrease visual acuity by 3 lines or more by end of 12 months 5. History of thermal lasers or treatment with intravitreal antiVEGF agents or steroids for any retinal conditions 6. Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug including those that has not received regulatory approval at the time of study entry 7. Anticipated major ocular surgery (including cataract extraction) for the period of the trial 8. Amblyopia in study eye 9. Known allergy to fluorescein dye or to any component of the study drug 10. Pregnancy at baseline and the patient will be withdrawn from the study if she becomes pregnant during the course of the study
    What will happen 2RT, nano second laser technology 400um spot size at least 25 spots
    Primary aim Visual acuity; Timepoint(s): 1 year
    Secondary Aim Not provided at time of registration
    Participant Information Sheet Sorry, not currently available
    Website Sorry, not currently available
    Recruitment Status Recruiting
    Nation England
    Location London
  • Contact

    -
    Contact for Public Queries Dr Sobha Sivaprasad Denmark Hill London SE5 9RS United Kingdom sobha.sivaprasad@nhs.net
    Contact for Scientific Queries Sorry, not currently available
Please note:
  1. The UKCTG information is designed to inform you of existing trials. If you wish to join a specific trial, you must discuss this with your own doctor who may decide to get in touch with the contact listed.
  2. The UKCTG is not responsible for the quality of the data displayed in the Gateway but can contact the data providers. Please contact us if you have any query regarding the quality of trial records.